Skip to content

A randomized double-blind controlled clinical study on the effectiveness of transcranial strong alternating current electrical stimulation in the treatment of schizophrenia.

A randomized double-blind controlled clinical study on the effectiveness of transcranial strong alternating current electrical stimulation in the treatment of schizophrenia.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086048
Enrollment
Unknown
Registered
2024-06-24
Start date
2024-02-19
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Control group:Received transcranial alternating current stimulation for the treatment of pseudostimulation

Sponsors

The Second People's Hospital of Guizhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 18~65 years old, male or female; Education level junior high school or above; Patients diagnosed with schizophrenia, depressive disorder, ADHD according to DSM-V criteria; (1) Enrollment criteria: a. PANSS scale total score >=60 ; b. Stable use of psychiatric drugs (dose, type of drug) for = 8 weeks; c. Good compliance, agree to participate in this study, and have informed consent signed by the guardian.

Exclusion criteria

Exclusion criteria: (2) Exclusion Criteria: a. mental retardation; b. Diagnosis of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) (DSM-V criteria) without sustained complete remission for at least 2 years prior to the screening visit; c. The patient is pregnant, lactating or planning to become pregnant; d. Those who are severely excited, restless, and restless and unable to maintain a sitting state; e. History of head injury, stroke, head tumor, Parkinson's, dementia, and seizures within 6 months prior to enrollment; f. Electroconvulsive therapy (ECT) or non-convulsive electroconvulsive therapy (MECT) within 6 months prior to enrollment; g. Inflammation of the skin of the head, head trauma, etc.; h. Allergy to alcohol, adhesive tape, conductive paste and metal electrodes; i. Possess implantable electronic devices, such as pacemakers, deep brain stimulators, etc.; j. Subjects who, in the opinion of the investigator, are not suitable to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
PANSS negative symptom subscale;PANSS positive symptom subscale;fNIRS;

Secondary

MeasureTime frame
EEG;SANS;SAPS;paranoia;Auditory Hallucinations Rating Scale (AHRS) Score;CGI;Multiple Object Tracking;MCCB;

Countries

China

Contacts

Public ContactShu Yanping

The Second People's Hospital of Guizhou Province

syp_8053@163.com+86 139 8540 2340

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026